These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9269520)

  • 1. Stability of omeprazole in an extemporaneously prepared oral liquid.
    Quercia RA; Fan C; Liu X; Chow MS
    Am J Health Syst Pharm; 1997 Aug; 54(16):1833-6. PubMed ID: 9269520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment.
    Meissner S; Bansal M; Dela CPD; Hanning S; Svirskis D
    Int J Pharm Compd; 2020; 24(2):140-147. PubMed ID: 32196476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability and viscosity of a flavored omeprazole oral suspension for pediatric use.
    Burnett JE; Balkin ER
    Am J Health Syst Pharm; 2006 Nov; 63(22):2240-7. PubMed ID: 17090745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid.
    Chuong M; Taglieri CA; Huang SY; Sariol A; Kitigawa R; Barman K; Mistry A; Harris DL; Kerr SG
    Int J Pharm Compd; 2019; 23(6):504-510. PubMed ID: 31751947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of partial doses of omeprazole-sodium bicarbonate oral suspension.
    Johnson CE; Cober MP; Ludwig JL
    Ann Pharmacother; 2007 Dec; 41(12):1954-61. PubMed ID: 17956960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
    Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C
    J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical stability of extemporaneously compounded omeprazole formulations: a comparison of two methods of compounding.
    Garg S; Svirskis D; Al-Kabban M; Farhan S; Komeshi M; Lee J; Liu Q; Naidoo S; Kairuz T
    Int J Pharm Compd; 2009; 13(3):250-3. PubMed ID: 23966480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid.
    Chuong MC; Taglieri CA; Kerr SG
    Int J Pharm Compd; 2017; 21(6):500-512. PubMed ID: 29220339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of flucytosine in an extemporaneously compounded oral liquid.
    Wintermeyer SM; Nahata MC
    Am J Health Syst Pharm; 1996 Feb; 53(4):407-9. PubMed ID: 8673661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of suspension formulations of lansoprazole and omeprazole stored in amber-colored plastic oral syringes.
    DiGiacinto JL; Olsen KM; Bergman KL; Hoie EB
    Ann Pharmacother; 2000 May; 34(5):600-5. PubMed ID: 10852086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of tacrolimus in an extemporaneously compounded oral liquid.
    Jacobson PA; Johnson CE; West NJ; Foster JA
    Am J Health Syst Pharm; 1997 Jan; 54(2):178-80. PubMed ID: 9117806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids.
    Allen LV; Erickson MA
    Am J Health Syst Pharm; 1996 Sep; 53(17):2073-8. PubMed ID: 8870895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical and chemical stability of esomeprazole sodium solutions.
    Kupiec TC; Aloumanis V; Ben M; Trissel LA; Chan P; Patterson J
    Ann Pharmacother; 2008 Sep; 42(9):1247-51. PubMed ID: 18614750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of an extemporaneously compounded levothyroxine sodium oral liquid.
    Boulton DW; Fawcett JP; Woods DJ
    Am J Health Syst Pharm; 1996 May; 53(10):1157-61. PubMed ID: 8734676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of atenolol in an extemporaneously compounded oral liquid.
    Garner SS; Wiest DB; Reynolds ER
    Am J Hosp Pharm; 1994 Feb; 51(4):508-11. PubMed ID: 8017418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between liquid protein solution and omeprazole suspension.
    Freeman KL; Trezevant MS
    Am J Health Syst Pharm; 2009 Nov; 66(21):1901-2. PubMed ID: 19850779
    [No Abstract]   [Full Text] [Related]  

  • 17. Stability of itraconazole in an extemporaneously compounded oral liquid.
    Jacobson PA; Johnson CE; Walters JR
    Am J Health Syst Pharm; 1995 Jan; 52(2):189-91. PubMed ID: 12879547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and evaluation of an omeprazole-based delayed-release liquid oral dosage form.
    Ronchi F; Sereno A; Paide M; Sacré P; Guillaume G; Stéphenne V; Goole J; Amighi K
    Int J Pharm; 2019 Aug; 567():118416. PubMed ID: 31175991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of ursodiol in an extemporaneously compounded oral liquid.
    Johnson CE; Nesbitt J
    Am J Health Syst Pharm; 1995 Aug; 52(16):1798-1800. PubMed ID: 8528836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of enalapril maleate in three extemporaneously prepared oral liquids.
    Nahata MC; Morosco RS; Hipple TF
    Am J Health Syst Pharm; 1998 Jun; 55(11):1155-7. PubMed ID: 9626379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.